Intravitreal Bevacizumab as an Adjunct Treatment for Neovascular Glaucoma

Hasanreisoğlu, Murat; Weinberger, Dov; Mimouni, Karin; Luski, Moshe; Bourla, Dan; Kramer, Michal; Robinson, Anat; Axer‐Siegel, Ruth

doi:10.1177/112067210901900414

Cited by 16 publications

(16 citation statements)

References 20 publications

(18 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…10 It has been reported as an effective treatment for angiogenesis in age-related macular degeneration, 11,12 branch and central retinal vein occlusion, 13 proliferative diabetic retinopathy, 14 and neovascular glaucoma. 15,16 There have been several reports in the literature to support the use of subconjunctival and topical bevacizumab for ocular surface neovascularization. 17,18 Bevacizumab also has been shown to be nontoxic to human corneal cells in vitro.…”

mentioning

confidence: 97%

Combined Use of Subconjunctival and Intracorneal Bevacizumab Injection for Corneal Neovascularization

Yeung

Lichtinger

Kim

et al. 2011

Cornea

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 97%

Combined Use of Subconjunctival and Intracorneal Bevacizumab Injection for Corneal Neovascularization

Yeung

Lichtinger

Kim

et al. 2011

Cornea

View full text Add to dashboard Cite

show abstract

“…They are also useful to reduce ischemic progression and to manage complications, such as neovascular glaucoma [61]. There are some prognostic factors for better outcome, such as better initial VA, no foveal hemorrhages, no macular ischemia, detection of VA gain after first injection, young age and final central retinal thickness [45,48,62,63].…”

Section: Treatmentmentioning

confidence: 99%

Retinal Vein Occlusion: Current Treatment

Lattanzio¹,

Gimeno

Parodi³

et al. 2010

Ophthalmologica

View full text Add to dashboard Cite

Retinal vein occlusion (RVO) is a pathology noted for more than 150 years. Although a lot has been written on the matter, it is still a frequent condition with multifactorial etiopathogenesis with many unclear aspects. The RVO pathogenesis has varied systemic and local implications that make it difficult to elaborate treatment guidelines. The management of the patient with RVO is very complex and a multidisciplinary approach is required in order to identify and correct the associated risk factors. Laser therapy remains the gold standard in RVO, but only modest functional improvement has been shown in branch retinal occlusion forms. Multicenter studies of intravitreal drugs present them as an option to combine with laser. Anti-vascular endothelial growth factor, corticosteroids and sustained-release implants are the future weapons to stop disease progression and get a better visual outcome. Consequently, it is useful to clarify some aspects of the pathology that allow a better patient management.

show abstract

“…There are reports that in elderly patients, this rise of intraocular pressure can precipitate the development of non-arteritic anterior ischemic optic neuropathy [ 299 , 300 ]. Other reported complications following anti-VEGF therapy include macular infarction [ 301 , 302 ], macular ischemia [ 303 ], development of a full-thickness macular hole [ 304 ], conversion of nonischemic CRVO to ischemic CRVO [ 305 ], glaucoma [ 306 -312 ], and progressive retinal nonperfusion [ 311 ]. Thus, one has to be aware of these rare complications of anti-VEGF therapy.…”

Section: Complications Of Intravitreal Anti-vegf Therapymentioning

confidence: 98%